BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ye H, Zhang XW, Mu R, Fang LK, Gu JR, Lin J, Du JF, Chen JW, Chen YJ, Wu LJ. Anti-TNF therapy in patients with HBV infection--analysis of 87 patients with inflammatory arthritis. Clin Rheumatol. 2014;33:119-123. [PMID: 24077913 DOI: 10.1007/s10067-013-2385-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Gargiulo L, Pavia G, Valenti M, Lleo de Nalda A, Perugini C, Costanzo A, Narcisi A. Safety of Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Viral Hepatitis: A Monocentric Retrospective Study. Dermatol Ther (Heidelb) 2022. [PMID: 35460018 DOI: 10.1007/s13555-022-00726-w] [Reference Citation Analysis]
2 Nard FD, Todoerti M, Grosso V, Monti S, Breda S, Rossi S, Montecucco C, Caporali R. Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs. World J Hepatol 2015; 7(3): 344-361 [PMID: 25848463 DOI: 10.4254/wjh.v7.i3.344] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 7.0] [Reference Citation Analysis]
3 Moghoofei M, Mostafaei S, Ashraf-Ganjouei A, Kavosi H, Mahmoudi M. HBV reactivation in rheumatic diseases patients under therapy: A meta-analysis. Microb Pathog 2018;114:436-43. [PMID: 29223453 DOI: 10.1016/j.micpath.2017.12.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
4 Lin TC, Yoshida K, Tedeschi SK, de Abreu MM, Hashemi N, Solomon DH. Risk of Hepatitis B Virus Reactivation in Patients With Inflammatory Arthritis Receiving Disease-Modifying Antirheumatic Drugs: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2018;70:724-731. [PMID: 28834412 DOI: 10.1002/acr.23346] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
5 Chen LF, Mo YQ, Jing J, Ma JD, Zheng DH, Dai L. Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation. Int J Rheum Dis. 2017;20:859-869. [PMID: 28160426 DOI: 10.1111/1756-185x.13010] [Cited by in Crossref: 47] [Cited by in F6Publishing: 25] [Article Influence: 9.4] [Reference Citation Analysis]
6 Koutsianas C, Thomas K, Vassilopoulos D. Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations. Ther Adv Musculoskelet Dis. 2020;12:1759720X20912646. [PMID: 32206094 DOI: 10.1177/1759720x20912646] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
7 Piaserico S, Messina F, Russo FP. Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations. Am J Clin Dermatol 2019;20:829-45. [PMID: 31222626 DOI: 10.1007/s40257-019-00457-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
8 Chen MH, Lee IC, Chen MH, Hou MC, Tsai CY, Huang YH. Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease. Ann Rheum Dis 2021:annrheumdis-2021-220774. [PMID: 34187776 DOI: 10.1136/annrheumdis-2021-220774] [Reference Citation Analysis]
9 Sayar S, Kürbüz K, Kahraman R, Öztürk O, Çalışkan Z, Doğanay HL, Özdil K. Risk of hepatitis B reactivation during anti-TNF therapy; evaluation of patients with past hepatitis B infection. Turk J Gastroenterol 2020;31:522-8. [PMID: 32897226 DOI: 10.5152/tjg.2020.19295] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Cholongitas E, Haidich AB, Apostolidou-Kiouti F, Chalevas P, Papatheodoridis GV. Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review. Ann Gastroenterol. 2018;31:480-490. [PMID: 29991894 DOI: 10.20524/aog.2018.0266] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
11 Koutsianas C, Thomas K, Vassilopoulos D. Prevention of HBV reactivation in patients treated with biologic agents. Expert Rev Clin Pharmacol. 2016; Epub ahead of print. [PMID: 26775683 DOI: 10.1586/17512433.2016.1143773] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
12 Fernández-Ruiz M, Aguado JM. Risk of infection associated with anti-TNF-α therapy. Expert Rev Anti Infect Ther 2018;16:939-56. [PMID: 30388900 DOI: 10.1080/14787210.2018.1544490] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
13 Smalls DJ, Kiger RE, Norris LB, Bennett CL, Love BL. Hepatitis B Virus Reactivation: Risk Factors and Current Management Strategies. Pharmacotherapy 2019;39:1190-203. [PMID: 31596963 DOI: 10.1002/phar.2340] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
14 Wroński J, Fiedor P. The Safety Profile of Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis: Are TNF Inhibitors Safer Than We Thought? J Clin Pharmacol 2019;59:445-62. [PMID: 30476367 DOI: 10.1002/jcph.1348] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
15 Viganò M, Serra G, Casella G, Grossi G, Lampertico P. Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders. Expert Opin Biol Ther 2016;16:917-26. [PMID: 27088278 DOI: 10.1080/14712598.2016.1177017] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
16 Fukuda W, Hanyu T, Katayama M, Mizuki S, Okada A, Miyata M, Handa Y, Hayashi M, Koyama Y, Arii K, Kitaori T, Hagiyama H, Urushidani Y, Yamasaki T, Ikeno Y, Suzuki T, Omoto A, Sugitani T, Morita S, Inokuma S. Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan. Ann Rheum Dis 2017;76:1051-6. [PMID: 27934678 DOI: 10.1136/annrheumdis-2016-209973] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 8.0] [Reference Citation Analysis]
17 Chiu YM, Chen DY. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. Expert Rev Clin Immunol 2020;16:207-28. [PMID: 31852268 DOI: 10.1080/1744666X.2019.1705785] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
18 Koutsianas C, Thomas K, Vassilopoulos D. Hepatitis B Reactivation in Rheumatic Diseases: Screening and Prevention. Rheum Dis Clin North Am 2017;43:133-49. [PMID: 27890170 DOI: 10.1016/j.rdc.2016.09.012] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
19 Chen YH, de Carvalho HM, Kalyoncu U, Llamado LJQ, Solano G, Pedersen R, Lukina G, Lichauco JJ, Vasilescu RS. Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice. Biologics 2018;12:1-9. [PMID: 29391775 DOI: 10.2147/BTT.S148606] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Chyuan IT, Hsu PN. Tumor necrosis factor: The key to hepatitis B viral clearance. Cell Mol Immunol 2018;15:731-3. [PMID: 29375133 DOI: 10.1038/cmi.2017.139] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
21 Louthrenoo W. Treatment considerations in patients with concomitant viral infection and autoimmune rheumatic diseases. Best Practice & Research Clinical Rheumatology 2015;29:319-42. [DOI: 10.1016/j.berh.2015.05.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
22 Chyuan IT, Tsai HF, Tzeng HT, Sung CC, Wu CS, Chen PJ, Hsu PN. Tumor necrosis factor-alpha blockage therapy impairs hepatitis B viral clearance and enhances T-cell exhaustion in a mouse model. Cell Mol Immunol. 2015;12:317-325. [PMID: 25661729 DOI: 10.1038/cmi.2015.01] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
23 Mok CC. Hepatitis B and C infection in patients undergoing biologic and targeted therapies for rheumatic diseases. Best Pract Res Clin Rheumatol 2018;32:767-80. [PMID: 31427054 DOI: 10.1016/j.berh.2019.03.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
24 Pauly MP, Tucker LY, Szpakowski JL, Ready JB, Baer D, Hwang J, Lok AS. Incidence of Hepatitis B Virus Reactivation and Hepatotoxicity in Patients Receiving Long-term Treatment With Tumor Necrosis Factor Antagonists. Clin Gastroenterol Hepatol 2018; 16: 1964-1973. e1. [PMID: 29702293 DOI: 10.1016/j.cgh.2018.04.033] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
25 Mori S, Fujiyama S. Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations. World J Gastroenterol 2015; 21(36): 10274-10289 [PMID: 26420955 DOI: 10.3748/wjg.v21.i36.10274] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 48] [Article Influence: 8.4] [Reference Citation Analysis]
26 Nunes GPS, Cunha PDS, Bosco DPD, Ribeiro SLE. Challenging Management of Hepatitis B infection in Ankylosing Spondylitis Patients in an Endemic Area during Immunosuppressive Therapy. Rev Soc Bras Med Trop 2019;52:e20180386. [PMID: 30892401 DOI: 10.1590/0037-8682-0386-2018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]